在乳腺癌患者中，他莫昔芬会改变胰岛素样生长因子（IGF）状态。

IGF status is altered by tamoxifen in patients with breast cancer.

作者信息

Campbell M J, Woodside J V, Secker-Walker J, Titcomb A, Leathem A J

机构信息

Department of Surgery, Royal Free and University College London Medical School, London, W1W 7EJ, UK.

出版信息

Mol Pathol. 2001 Oct;54(5):307-10. doi: 10.1136/mp.54.5.307.

DOI:10.1136/mp.54.5.307

PMID:11577172

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1187087/

Abstract

AIMS

An increased concentration of insulin-like growth factor 1 (IGF-1) is an independent risk factor for premenopausal breast cancer. Tamoxifen is thought initially to reduce concentrations of IGF-1 and increase concentrations of the IGF binding proteins. The aim of this study was to compare concentrations of IGF-1, IGF binding protein 1 (IGF-BP1), and IGF-BP3 in patients with breast cancer (n = 14) with those seen in control subjects (n = 23) and to assess the effect of tamoxifen on IGF status in these patients.

METHODS

Non-fasting blood samples were collected from patients with breast cancer before surgery and after nine, 18, and 27 months of tamoxifen treatment. The baseline concentrations were compared with those of age and sex matched healthy control subjects.

RESULTS

IGF-1, IGF-BP3, and IGF-BP1 concentrations were not significantly different in cases and controls. Tamoxifen treatment significantly increased IGF-BP1 after 18 and 27 months (baseline: mean, 21.6 ng/ml; SD, 16.6; 18 months: mean, 52.0 ng/ml; SD, 41.8; p = 0.019; 27 months: mean, 40.7 ng/ml; SD, 24.9; p = 0.043) and IGF-BP3 after nine, 18, and 27 months (baseline: mean, 3119 ng/ml; SD, 507; nine months: mean, 3673 ng/ml; SD, 476; p = 0.004; 18 months: mean, 3445 ng/ml; SD, 634; p = 0.034; 27 months: 3409 ng/ml; SD, 501; p = 0.043) when compared with baseline values. IGF-1 was not altered significantly from baseline at any time point. However, the IGF-1 to IGF-BP3 ratio was significantly decreased at both nine and 18 months (baseline: mean, 0.058; SD, 0.014; nine months: mean, 0.039; SD, 0.008; p = 0.033; 18 months: mean, 0.044; SD, 0.012; p = 0.01). This ratio was not significantly different from baseline at 27 months (mean, 0.054; SD, 0.01; p = 0.08).

CONCLUSIONS

Tamoxifen increases IGF-BP3 and IGF-BP1 concentrations. It also decreases the IGF-1 to IGF-BP3 ratio but this effect may be limited after long term use. Longer follow up, with larger numbers of patients, should determine when, and for how long, tamoxifen can reduce circulating IGF-1.

摘要

目的

胰岛素样生长因子1（IGF-1）浓度升高是绝经前乳腺癌的一个独立危险因素。他莫昔芬最初被认为可降低IGF-1浓度并增加IGF结合蛋白的浓度。本研究的目的是比较乳腺癌患者（n = 14）与对照受试者（n = 23）中IGF-1、IGF结合蛋白1（IGF-BP1）和IGF-BP3的浓度，并评估他莫昔芬对这些患者IGF状态的影响。

方法

在乳腺癌患者手术前以及他莫昔芬治疗9、18和27个月后采集非空腹血样。将基线浓度与年龄和性别匹配的健康对照受试者的浓度进行比较。

结果

病例组和对照组的IGF-1、IGF-BP3和IGF-BP1浓度无显著差异。他莫昔芬治疗18个月和27个月后，IGF-BP1显著升高（基线：平均值，21.6 ng/ml；标准差，16.6；18个月：平均值，52.0 ng/ml；标准差，41.8；p = 0.019；27个月：平均值，40.7 ng/ml；标准差，24.9；p = 0.043），9个月、18个月和27个月后IGF-BP3显著升高（基线：平均值，3119 ng/ml；标准差，507；9个月：平均值，3673 ng/ml；标准差，476；p = 0.004；18个月：平均值，3445 ng/ml；标准差，634；p = 0.034；27个月：3409 ng/ml；标准差，501；p = 0.043），与基线值相比。IGF-1在任何时间点与基线相比均无显著变化。然而，IGF-1与IGF-BP3的比值在9个月和18个月时均显著降低（基线：平均值，0.058；标准差，0.014；9个月：平均值，0.039；标准差，0.008；p = 0.033；18个月：平均值，0.044；标准差，0.012；p = 0.01）。该比值在27个月时与基线无显著差异（平均值，0.054；标准差，0.01；p = 0.08）。